CSBio CSBio

X
[{"orgOrder":0,"company":"Hutchmed","sponsor":"Baring Private Equity Asia","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hutchmed Announces US$100 Million Equity Investment by Baring Private Equity Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$104.0 million","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Launches Hong Kong Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Announces First Commercial Sale of ORPATHYS\u00ae in China, Triggering a US$25 million Milestone Payment from AstraZeneca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE\u00ae and Addition of SULANDA\u00ae in the National Reimbursement Drug List in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Receives Approval to Commercialize ELUNATE\u00ae in Macau","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Epizyme","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces TAZVERIK Approved to be Used in Hainan Pilot Zone in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed\/Refractory Follicular Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hutchmed Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS\u00ae in the National Reimbursement Drug List in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,130.0 million","upfrontCash":"$400.0 million","newsHeadline":"HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,130.0 million","upfrontCash":"$400.0 million","newsHeadline":"HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Receives ELUNATE (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchmed"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chi-Med and Lilly to Collaborate in Commercializing Elunate\u00ae in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchison China MediTech"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchison China MediTech"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda\u00ae in China) for Non-Pancreatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hutchison China MediTech"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Elunate (fruquintinib) is a selective oral inhibitor of VEGF receptors. It is approved in Hong Kong for the treatment of metastatic colorectal cancer.

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis and designed to improve kinase selectivity with the intention of minimizing off-target toxicities.

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Takeda will receive worldwide license to develop and commercialize HMPL-013 (fruquintinib) from HUTCHMED in metastatic CRC and territories outside of mainland China, Hong Kong and Macau. Fruquintinib has been approved in China under the brand name ELUNATE.

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: $1,130.0 million Upfront Cash: $400.0 million

            Deal Type: Licensing Agreement March 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Takeda will receive worldwide license to develop and commercialize HMPL-013 (fruquintinib) from HUTCHMED in metastatic CRC and territories outside of mainland China, Hong Kong and Macau. Fruquintinib has been approved in China under the brand name ELUNATE.

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: $1,130.0 million Upfront Cash: $400.0 million

            Deal Type: Licensing Agreement January 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ORPATHYS® (savolitinib), an oral, potent and highly selective MET tyrosine kinase inhibitor, has been included in the updated National Reimbursement Drug List for the treatment of locally advanced or metastatic NSCLC adult patients with MET exon 14-skipping alterations.

            Lead Product(s): Savolitinib

            Therapeutic Area: Oncology Product Name: Orpathys

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Healthcare Security Administration

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities.

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 19, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Elunate (Fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Elunate (fruquintinib) is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Fruquintinib is a highly selective and potent oral inhibitor of VEGFR-1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability.

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY